New drug hope for rare autoimmune disease? tiny trial begins
NCT ID NCT05504694
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests the drug ofatumumab in 5 people with a rare autoimmune disease called NMOSD. Participants receive injections over 48 weeks. The main goal is to see if the drug reduces the number of relapses compared to before treatment. It is an early, small study focused on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ofatumumab (a drug injected under the skin)
- What this could lead to
- If it works, this could point toward a new treatment option to reduce relapses in NMOSD.
- What could go wrong
- This is a very small, early-phase pilot study with only 5 participants, so results may not apply to everyone. The drug may not reduce relapses or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospital
RECRUITINGXi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases
- Experimental CAR t treatment targets root cause of rare nerve disease